Xenon Reports First Quarter 2025 Financial Results and Provides Business Update VANCOUVER, BC and BOSTON, MA, May 12, 2025 – Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience- focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today reported financial results for the first quarter ended March 31, 2025, and provided a business update. "We continue to make steady progress across our Phase 3 epilepsy program, with pati ...